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What you need to know
• Patients taking immunomodulatory therapy require
regular blood test monitoring to identify adverse drug
reactions such as hepatotoxicity and bone marrow
suppression
• Monitoring levels vary considerably, with
under-monitoring and over-monitoring being common
• Multiple guidelines exist, with some variation in
recommended practice, although recommendations
tend to be based on expert consensus
Immunomodulation is the cornerstone of treatment
in many immune mediated inflammatory disorders,
including inflammatorybowel disease, autoimmune
rheumatic disease, and inflammatory skin diseases.
Most require pre-treatment screening blood tests and
regular blood test monitoring thereafter to detect
potential toxicity. This article seeks to provide a
simplified overview of blood test monitoring
requirements, and is aimed at general practitioners
who, increasingly, are taking responsibility for
monitoring and prescribing these medications.
What patients say
Patients may have concerns about taking an
immunomodulatory medication. We held a focus group
with eight patients who were taking immunomodulatory
therapy (three with Crohn’s disease and five with
ulcerative colitis), who told us:
• They are often concerned about too much suppression
of the immune system, especially when risks of
infection are discussed
• They often find it difficult to attend for regular
monitoring blood tests as services for people of
working age are not always available, and systems
of testing can be frustrating
• They often do not feel in control of their blood
monitoring as feedback from blood tests can be
intermittent
What conditions are commonly monitored
in general practice?
General practitioners care for awide range of patients
whoare treatedwith immunomodulators. Commonly
prescribed immunomodulators are listed in box 1.
The conditions treated include psoriasis (UK
prevalence 2.2-2.8%2), rheumatoid arthritis (UK
prevalence 1%3), and inflammatory bowel disease
(worldwideprevalence 0.3%4). In theUK, prescribing
responsibilities are transferred from specialist care
to primary care using Effective Shared Care
Agreements, written local agreements between
specialist services and GPs. A large proportion of GPs
are either directly involved in caring for patients on
immunomodulators or come into contact with them
on a regular basis and should therefore be aware of
thedrug toxicities andmonitoring recommendations.
Box 1: Immunomodulators commonly prescribed in
inflammatory disease
Initiated in secondary care with ongoing monitoring,




• Thiopurines (including azathioprine,
6-mercaptopurine)
• Leflunomide
• Hydroxychloroquine (no routine laboratory monitoring
is required)1
Generally monitored in secondary care
• Ciclosporin, mycophenolate mofetil, tacrolimus
• Biological/monoclonal antibody agents, including
tumour necrosis factor-alpha inhibitors, T-cell
activation inhibitors, interleukin inhibitors,
Janus-associated tyrosine kinase inhibitors, and
B-lymphocyte associated monoclonal antibodies
Why is monitoring important?
Immunomodulators can cause significant adverse
events, including hepatotoxicity, leucopenia, and
neutropenia. Theprevalence ofmild and/or transient
blood test abnormalities is relatively common. For
example, in a large cohort study of 10 863 patients
with rheumatoid arthritis or psoriatic arthritis taking
disease-modifying anti-rheumatic drugs, liver
enzymes above the reference range occurred in
14-22%of cases, dependingon thedrug combination;
while severe reactions (>2× upper limit of normal)
occurred in 1-2% of cases.5 In a meta-analysis of 66
studies comprising 8302 patients with inflammatory
bowel disease on 6-mercaptopurine/azathioprine,
the cumulative incidence of myelotoxicity was 7%.
The cumulative incidence of severe myelotoxicity
was 1.1%.6 Mortality rates among patients with
inflammatory bowel disease who developed
myelotoxicity were low at 0.94%.6 While mild blood
test abnormalities are frequent, they are generally
transient and even cases with severe blood test
abnormalities resolve promptlywith discontinuation
or dose reduction.7 Serial abnormal tests are more
likely to be associated with pathological liver/bone
marrow disease, but risk of progression to serious
disease is difficult to assess given that drug exposure
is stopped or reduced in most cases.7 Furthermore,
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some uncertainty exists around the degree of risk for liver toxicity
attributable tomethotrexate treatment, independent to that of other
risk factors and pre-existing liver pathology.7 However, guidelines
from the British Society for Rheumatology for methotrexate provide
evidence showing, for example, that abnormal liver enzymes are
predictive of histological findings on liver biopsy.1 Monitoringneeds
to balance detection of abnormalities that may lead to harm against
those commonly seen abnormalities that are mild or transient and
potentially lead to over-investigation.
Howis immunomodulatorytherapy initiated insecondary
care?
Several baseline screening tests should be undertaken before
starting treatment, to assess the risks of serious side effects
associated with the particular drug.1 8 -15 These tests (eg, for
pregnancy and occult infection) are generally arranged by
specialists. Patients may be directed to their GP to ensure that
relevant vaccinations are up to date. Some agents, such as
leflunomide and methotrexate, are contraindicated in pregnancy.
Monitoring for adverse effects immediately after starting treatment,
or after a dose change, is generally the responsibility of specialists.
These blood tests largely reflect those used for longer-term
monitoring, but with increased frequency (every 1-2 weeks) until
stable dosing is achieved (usually within 1-3 months13). Further
details can be found in specialist guidance.1 8 -15
Regular, long term monitoring (ie, for the duration of treatment
with the drug while on a stable dose) is often performed in general
practice, although in some cases thismay remain the responsibility
of specialists. Effective andexplicit handover of care fromspecialists
to general practitioners is critical and needs to be understood by
all parties, including the patient. In the UK, this should be done via
an Effective Shared Care Agreement, which should clearly detail
which tests are required, who is responsible for testing, how often,
and what action is needed in the event of abnormalities.
Furthermore, at an individual patient level, communication from
specialist outpatient clinics should include a statement regarding
the ongoing monitoring requirements.
What do guidelines say about monitoring requirements
for long term treatment?
Guidance on which blood tests to perform and the frequency of
testing is provided by the relevant professional bodies, the National
Institute for Health and Care Excellence (NICE) and the British
National Formulary (BNF)18 -15 and is summarised in the infographic.
These guidelines are generally in agreement in terms of which tests
to undertake and the frequency of monitoring: 8-12 weekly for full
blood counts and liver function tests to identify any bone marrow
or hepatic toxicity, and renal function tests to assess capacity for
drug clearance (eg, for renally excreted drugs such as
6-mercaptopurine/azathioprine, which can exacerbate risk of
toxicity) and/or nephrotoxicity itself (eg, for drugs such as
methotrexate). The exception is the American College of
Gastroenterology guidelines15 which do not recommend an explicit
frequency for blood testing, stating only that tests should be done
“regularly.”
In specific cases, additional tests are recommended. For example,
in patients with psoriasis on methotrexate, measurement of
procollagen III N-terminal peptide is also advised as an indicator
of hepatic fibrosis, although this is usually performed in secondary
care.9 Monitoring requirements are tailored to individual risks, and
the recommendations described here and in the infographic are
provided only as a guide. Somepatients, such as thosewith relevant
comorbidities (eg, malignancy) or on multi-agent therapy (eg,
combination therapy as is commonly used in rheumatoid arthritis)




Variations exist between guidelines on drugs and conditions in the
UK1 8 -13 and elsewhere,14 15 particularly in the action limits (ie, blood
test values outside which clinical action is warranted) used,
although the principles remain the same (supplementary file).
6-mercaptopurine/azathioprine
For 6-mercaptopurine/azathioprine, the British Society for
Rheumatology guidelines suggest monitoring a wider range of
parameters, including eosinophils, platelets, mean corpuscular
volume, andalbumin,1 whicharenotmentioned inother guidelines.
Slight variations in action limits are also evident for neutrophils,
transaminases, and assessment of renal function. While in each
case guidelines suggest contacting respective specialists, the
wording varies in intensity. For instance, the British Society for
Rheumatology guidelines state for abnormal transaminases:
“Contact rheumatology team urgently and consider interruption in
treatment,”1 while the British Society of Gastroenterology uses the
phrase “Stop and check thiopurine metabolites” (a test requested
by specialists).10 The British Association of Dermatologists
recommendations imply a more pragmatic approach to abnormal
results based on more “careful evaluation and increased frequency
of repeat testing,” although it does acknowledge that “dose
reduction or drug withdrawal may be needed.”
Methotrexate
For methotrexate, the British Society for Rheumatology guidelines
are the same as for 6-mercaptopurine/azathioprine.1 By contrast,
the British Association of Dermatologists does not include
eosinophils or albumin in its recommendations for monitoring
methotrexate, and in cases of abnormal results, suggests discussion
with haematology or gastroenterology in cases of suspected myelo
or hepatotoxicity, respectively.9 The British Society of
Gastroenterology guidelines for methotrexate require monitoring
for a more limited range of parameters (white cell count and
transaminases only) and suggest stopping treatment if these are
outside action limits.10
Leflunomide and sulfasalazine
Recommendations on handling abnormal results for patients on
leflunomide and sulfasalazine are only provided in the British
Society for Rheumatology guidelines and mirror those used for
patients taking6-mercaptopurine/azathioprine andmethotrexate.10
In all cases, results of laboratory tests should be interpreted in the
context of the individual patient, the severity, the speed of change
of any abnormalities, and the expected action of the therapeutic
agent. For example, a sudden change in liver function test results
in an ostensibly asymptomatic patient who has otherwise tolerated
a drug well may reflect other causes of liver damage. In this context,
awareness of local pathways for managing patients with abnormal
test results is important.
Practical challenges
Growing evidence suggests that the number of patients who are
underandover-testedwhencomparedwithguidance is considerable
and highly variable across a range of conditions.16 -18 Reasons for
this are complexandmultifactorial, but includepatient, practitioner,
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and system factors (table 1).16 17 Included in this is the frequent need
for interaction between primary and secondary care, and the
availability of specialist advice. The implications of under and
over-testing are significant. For instance, under-testing risks adverse
events such as liver damage or bone marrow suppression, while
over-testing is costly to the NHS, increases the workload of
over-stretched primary care services, and risks false positives and
over-diagnosis. In addition, frequent testing is inconvenient for
patients (eg, timeoffwork, discomfort, costs),17 18 potentially having
anegative effect on the acceptability of their treatment plan. Testing
strategies therefore need to balance safety, cost, deliverability, and
the burden of monitoring for patients.
Table 1 | Tips for improving monitoring
Improvement optionsFactor
1. Convenience: Could phlebotomy services be provided outside normal working hours or in a
more convenient location?
2. Education and motivation: Does the patient understand the need for the test? Could patient
information emphasise this?
3. Engagement: How can test results best be provided and explained to patients?
Patient
1. Responsibility: Is it clear who is responsible for organising the testing? Are the methods used
to hand over this responsibility between specialist and general practice effective?
2. Education: Are the key healthcare professionals aware of the need and importance of testing?
3. Motivation: Are clinicians clear on the benefits of monitoring? What are the incentives?
Clinician
1. Infrastructure: Is there a system for identifying patients who need testing and when the next
test is due?
2. Test requesting: Are there more user-friendly ways of requesting appropriate tests, such as
by using standardised test panels for specific drugs via electronic test requesting systems.
3. Results visibility: Are primary and secondary care staff able to view results requested by the
other?
4. Engagement: Are laboratory staff engaged in providing support (technical, logistic and
educational)?
System
Improvements in monitoring will need to address the evidence
underpinning the frequency of testing and ensure that healthcare
infrastructure is in place, such as by use of electronic reminder
systems.19 20 Critically, approaches to reduceunder andover-testing
will need to engage patients, such as by making sample collection
more convenient and enabling patients to be more involved in
managing their condition by providing access to test results and/or
educational advice on the importance of testing.17 21 Given their
existing involvement in blood testing for specialists and general
practitioners, clinical laboratoriesmaybeuniquelyplaced tooversee
this monitoring service.
Uncertainties
The guidance on monitoring for many of the common agents is clear and
broadly similar; however, high quality evidence on which to base these
recommendations is lacking, and recommendations are frequently based
on expert opinion. For example, the level of evidence for
recommendations on acting on abnormal test results for patients on
methotrexate in the 2016 British Association of Dermatologists’ guidelines
on psoriasis9 was identified as 2+ (based on well conducted case-control
or cohort studies). British Society of Gastroenterology recommendations
for blood test monitoring 6-mercaptopurine, azathioprine, or methotrexate
in patients with inflammatory bowel disease were graded as based on
“low-quality evidence,” and the British Society for Rheumatology
guidelines for monitoring disease modifying anti-rheumatic drugs
(DMARDs) were graded as 2B (weak recommendations based on moderate
evidence).1 The authors of a systematic review of thiopurine-induced
liver injury in patients with inflammatory bowel disease concluded:
“Despite a lack of evidence that monitoring of liver tests is necessary in
patients receiving 6-mercaptopurine/azathioprine, routinely performed
laboratory controls including liver tests seem recommendable.”22 The
need for additional evidence is highlighted by a recent call from the UK
National Institute for Health Research Health Technology Assessment
funding stream for studies to provide evidence on testing frequency
specifically for patients with common inflammatory diseases. This
includes the need to assess patient views on what is often relatively
frequent and potentially inconvenient testing.
Impact of covid-19
In the context of covid-19, some variations exist on guidance for blood
test monitoring in established immunomodulatory therapy:
• The British Society of Gastroenterology advises reducing any
therapy-associated monitoring blood tests to minimum safe frequency,
and suggests that many routine tests can be deferred until the
situation has improved, depending on local capacity23
• The British Association of Dermatologists advises that patients who
have been on the same medication for a substantial period of time
with adequate disease control and blood monitoring that has remained
satisfactory may be able safely to increase the time interval for blood
monitoring on a case-by-case basis24
• The British Society for Rheumatology advises that clinicians may need
to be flexible about blood testing and that it is usually safe to reduce
blood testing frequency to three-monthly or even less in stable
patients. It states that cases need to be reviewed on an individual
basis, weighing up the risks of continuing without blood testing,
compared with the benefit of staying on DMARDS25
• Guidance for monitoring during initiation remains unchanged.
• NICE recommends that patients follow comprehensive social
distancing and hand hygiene measures for 14 days before having
planned care; this includes diagnostic tests.26
• For individuals with symptoms associated with covid-19, the British
Society for Rheumatology guidance also suggests:25
‐ considering stopping medication and seeking specialist advice
on when to restart
‐ undertaking additional blood tests after self-isolation and within
two weeks of restarting medication
‐ if these tests are within the normal range, reverting to a flexible
monitoring schedule on a case-by-case basis (see above); if
abnormal, seek specialist advice
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Education in to practice
• What impact does immunomodulatory treatment and monitoring have
on your patients’ quality of life?
• What systems do you have in place to ensure adequate monitoring?
• How well does your patients’ blood test monitoring conform to
guidelines? Consider auditing attendance for blood tests, frequency
of abnormalities, and patient recall for abnormalities
How this article was made
We reviewed the British National Formulary, current guidelines from the
National Institute for Health and Care Excellence and major professional
bodies including the American Academy of Dermatology, American Society
of Gastroenterology, American College of Rheumatology, British
Association of Dermatologists, British Society for Rheumatology, British
Society for Paediatric and Adolescent Rheumatology, British Society of
Gastroenterology, British Society of Paediatric Gastroenterology,
Hepatology and Nutrition, European Crohn’s and Colitis Organisation,
and the North American Society for Pediatric Gastroenterology,
Hepatology, and Nutrition. We reviewed UK national Effective Shared
Care Agreements. We searched the Cochrane database and Medline using
the search terms “Guidelines,” “DMARD(s),” “Immunomodulators,”
“Monitoring,” “Blood Test Monitoring,” “Thiopurine,” “Azathioprine,”
“Methotrexate,” “Leflunomide,” “Sulfasalazine,” “Hydroxychloroquine
& Adverse events.”
How patients were involved in the creation of this article
We held a focus group with eight patients who are receiving
immunomodulatory treatment and asked them about the impact of their
treatment on their daily lives. Their responses informed the “What the
patients say” box and the focus throughout the article on the impact of
monitoring on patients.
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